Viewing nowPregabalin Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.

MFDS item code 201603606 · Approved 2016.06.20 · Insurance code 648603320
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjuvant for partial seizures in patients with epilepsy. It also helps alleviate symptoms in patients with fibromyalgia. It is effective for various nerve-related disorders.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is primarily excreted by the kidneys, so the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be started at 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment Dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a: Starting dose (mg/day), Maximum dose (mg/day) | Method of administration ≥60 | 150, 600 | BID or TID ≥30 -<60 | 75, 300 | BID or TID ≥15 -<30 | 25-50, 150 | QD or BID <15 | 25, 75 | QD Supplemental dose after hemodialysis | 25, 100 | Single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Use is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if you experience mood changes or abnormal behavior while taking it, you should inform your healthcare provider immediately. Do not take this medication if you are allergic to any of its components or have certain genetic metabolic disorders. Diabetic patients may need to adjust their blood sugar control medications due to weight gain, so caution is advised. If serious allergic reactions such as angioedema occur, stop taking the medication immediately and seek medical attention. Elderly patients should take caution as this medication may cause dizziness or drowsiness, increasing the risk of falls. Vision changes or other visual disturbances may occur, and if such symptoms arise, discontinuation of the medication may be considered. Abruptly stopping this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety, so it is advisable to consult your healthcare provider for gradual dosage adjustment. Patients with a history of drug abuse may have a higher risk of misuse of this medication, necessitating careful assessment before use. Patients with impaired kidney function may require dosage adjustments, so kidney status should be monitored regularly. Patients with severe heart disease should use caution when taking this medication as cardiovascular side effects may occur. Co-administration with opioid analgesics may enhance central nervous system depressive effects, increasing the risk of respiratory distress, so care must be taken. In early pregnancy, there is a risk of fetal malformations, so it is advisable to avoid using this medication during pregnancy, and fertile women should use effective contraception. During breastfeeding, this medication may be transferred through breast milk and could affect infants, so consideration should be given to discontinuing breastfeeding or the medication. Before driving or operating hazardous machinery, check for dizziness or drowsiness caused by this medication and exercise caution. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatments such as hemodialysis may be necessary.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture, and keep it in a cool place between 15 and 30 degrees Celsius.
A white capsule with white powder that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
CMG Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.